Minerva Neurosciences | NERV - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Adma Biologics USD 26.74M 6.55M 2026-03
ALKERMES USD 196.64M 67.96M 2026-06
Alterity Therapeutics Limited AUD 1.45M 703.96K 2025-12
AstraZeneca USD 5.8B 735M 2026-06
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Cipla INR 13.25B 101.8M 2025-12
Clal Biotechnology ILS 3.31M 513K 2022-12
Compugen USD 2.43M 222K 2026-03
CSL USD 1.23B 498M 2025-12
Eli Lilly USD 3.43B 496M 2026-06
GlaxoSmithKline GBP 2.19B 75M 2026-06
Grifols EUR 320.45M 12.65M 2025-12
Halozyme Therapeutics USD 57M 10.71M 2026-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
J&J USD 6.42B 381M 2026-06
Merck USD 2.89B 219M 2026-06
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.24B 101M 2026-06
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 3.41B 496M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.63B 307M 2026-06
Takeda JPY 286.51B 5.48B 2026-06
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12